This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of other and unspecified parts of tongue혀의 기타 및 상세불명 부분의 악성신생물 (설암)

Contents and key points
ItemDetails
A. Classification codesICD-10: C02 | Special Copayment Reduction: V193 (copayment 5% for care of the relevant condition for 5 years from the date of cancer patient registration)
B. SynonymsTongue cancer, cancer of the tongue, oral tongue cancer; Oral tongue cancer, Tongue squamous cell carcinoma, Lateral tongue carcinoma, Ventral tongue carcinoma
C. Adult onsetLikelihood of first onset in adulthood very high — mostly diagnosed in the 40s–70s, with a recent trend of increasing incidence in women aged 45 and under
1. HistoryOral tumors recognized since antiquity, systematization of surgical glossectomy in the 19th century, introduction of radiation and chemotherapy in the 20th century, integration of the depth of invasion (DOI) concept into staging in the 21st century
2. CausesSmoking (major), alcohol, poor oral hygiene, chronic mechanical irritation, betel nut, HPV, immunosuppression, nutritional deficiency
3. GeneticsSomatic mutations of TP53 (38%), CDKN2A, NOTCH1, FAT1, CASP8, PIK3CA; EGFR overexpression; high risk in Fanconi anemia; molecular markers related to depth of invasion
4. General epidemiologySecond most common site of oral cancer worldwide; about 800–1,000 tongue cancer cases per year in Korea; male predominance; recent increase in young women; regional and socioeconomic disparities
5. PathophysiologyMultistep carcinogenesis, progression from mucosal intraepithelial neoplasia (OED) → invasive cancer, activation of EGFR, PI3K, Wnt and Notch pathways, role of depth of invasion and perineural invasion
6. SymptomsEarly: painless ulcer or leukoplakia on the lateral or ventral tongue; advanced: pain, odynophagia, dysarthria, trismus, neck mass
7. SignsUlcerative mass on the lateral or ventral tongue, cervical lymphadenopathy, restricted tongue movement, perineural invasion, muscle and bone invasion on imaging
8. ScreeningNational visual oral cancer examination, regular dental checkups, self-examination education, regular endoscopic surveillance of high-risk groups (smoking, alcohol, premalignant lesions)
9. DiagnosisCT, MRI, PET-CT, biopsy, measurement of depth of invasion (DOI), staging (DOI incorporated into AJCC 8th edition T classification), sentinel lymph node biopsy, assessment of perineural invasion
10. TreatmentSurgery (glossectomy + neck dissection), adjuvant radiotherapy, concurrent chemoradiotherapy, reconstruction (free flap); recurrence/metastasis: pembrolizumab, nivolumab, cetuximab
11. PrognosisEarly (stage I) 5-year survival 75–85%, dropping sharply to 22–40% with lymph node metastasis; DOI, perineural invasion and surgical margins are the key prognostic factors
12. PreventionSmoking cessation and moderate drinking (most effective), oral hygiene, HPV vaccine, regular dental checkups, early treatment of premalignant lesions
13. ReferencesBray F et al. Global cancer statistics 2022. CA Cancer J Clin. 2024 ... and 9 other papers

1. History

Tongue cancer is one of the oral malignancies recorded longest in human history. Ulcerative lesions of the tongue are mentioned in ancient Egyptian papyri and Hippocratic writings, and Galen described hard masses of the tongue as a kind of 'cancer (karkinos).' However, treatment was limited to cauterization and simple excision, and the prognosis was extremely poor.

With the establishment of modern surgery, surgical treatment of tongue cancer began in earnest. In 17th-century Europe, partial glossectomy was attempted sporadically, and in the late 18th to early 19th centuries, developments in anesthesia and aseptic surgery made more extensive resections possible. The German Theodor Billroth described systematic surgical resection of oral cancer in 1881, after which the technique of surgical glossectomy was gradually standardized. Radical neck dissection was systematized by George W. Crile Sr. in the early 20th century and became the foundation of head and neck cancer treatment.

In the mid-20th century, advances in radiotherapy greatly changed the treatment of tongue cancer. Along with external beam radiation, interstitial radiation (brachytherapy) began to be used effectively for early tongue cancer. In the 1970s–1980s, cisplatin-based chemotherapy was introduced, establishing combined-modality therapy given before or after surgery or concurrently with radiation.

In the 21st century, as the prognostic importance of depth of invasion (DOI) was established, the AJCC 8th edition in 2017 formally incorporated DOI into the T classification. This was a historic turning point in which staging of tongue cancer evolved from simple size to a three-dimensional concept of invasion depth. In addition, sentinel lymph node biopsy (SLNB) is being studied as an alternative to elective neck dissection in early tongue cancer. In Korea, since the 2000s, head and neck multidisciplinary teams (MDT) at the National Cancer Center and major university hospitals have led the standards for diagnosis and treatment of tongue cancer.


2. Causes

Malignant neoplasms of other and unspecified parts of the tongue (C02) arise mainly in the anterior two-thirds of the tongue (oral tongue), including the dorsum, lateral border, ventral surface (underside) and tip of the tongue. Unlike base-of-tongue cancer (C01), cancer at these sites has a low association with HPV, and smoking and alcohol are the main causes.

Smoking

Carcinogens in tobacco smoke such as polycyclic aromatic hydrocarbons (PAH), nitrosamines, benzopyrene and formaldehyde directly damage the DNA of oral mucosal epithelial cells. Smoking raises the risk of tongue cancer 4–6 times compared with nonsmokers, and the risk rises in proportion to the amount (pack-years) and duration of smoking. After quitting smoking, the risk decreases gradually over time.

Alcohol

Acetaldehyde, a metabolite of ethanol, breaks DNA strands and causes abnormal methylation. Alcohol itself also increases the permeability of the oral mucosa to carcinogens, producing an indirect carcinogenic effect. Combined exposure to smoking and alcohol has a synergistic carcinogenic effect, and with simultaneous exposure the risk increases several-fold compared with either exposure alone.

Poor oral hygiene and chronic irritation

Chronic mechanical irritation from sharp margins of poor prostheses, ill-fitting dentures and broken teeth causes chronic ulcers on the lateral tongue, and these sites can undergo malignant transformation. Poor oral hygiene is associated with abnormal oral bacterial diversity, creating a carcinogenic environment.

HPV and others

The proportion of HPV-related oral tongue cancer is much lower than for base-of-tongue cancer (5–15%), but HPV-16 infection is confirmed in some cases. Betel nut (areca) chewing is a major cause of oral cancer in Southeast and South Asia, and attention is also needed in immigrant populations in Korea. Immunosuppressed states (HIV infection, after organ transplantation), deficiencies of vitamins A, C and E, and iron deficiency anemia (Plummer-Vinson syndrome) are also known risk factors.


3. Genetics

Oral tongue cancer is mostly HPV-negative, and the accumulation of somatic mutations due to smoking, alcohol and environmental carcinogens is the main mechanism of carcinogenesis. The genetic alteration landscape of oral tongue cancer has been characterized in detail through TCGA (The Cancer Genome Atlas) and several large molecular studies.

Major somatic mutations

TP53 mutation is the most common alteration, observed in about 38–80% of oral tongue cancers, and loss of tumor suppressor function weakens apoptosis and the DNA damage response. Deletion of CDKN2A (p16) or silencing by methylation leads to loss of the G1/S cell cycle checkpoint. Loss-of-function mutations of FAT1 (of the cadherin cell-adhesion family) and NOTCH1 are also frequent. Activating mutations of PIK3CA (4–15%) hyperactivate the PI3K/AKT/mTOR pathway, and CASP8 mutations are associated with resistance to apoptosis. An association between alcohol and chewing tobacco exposure and RASA1 mutation has also been reported.

Molecular subtypes and EGFR

EGFR is overexpressed in 80–90% of oral tongue cancers, with simultaneous activation of the downstream MAPK and PI3K pathways. EGFR overexpression correlates with poor prognosis and provides the theoretical basis for EGFR-targeted therapy such as cetuximab. As a molecular marker related to depth of invasion (DOI), overexpression of MMP-10 (matrix metalloproteinase-10) is being studied as a predictor of cervical metastasis.

Hereditary syndromes

Fanconi anemia (mutations of DNA double-strand repair genes such as FANCA) is a strong risk factor for head and neck and oral cancer arising at a young age. Li-Fraumeni syndrome (germline TP53 mutation) and Bloom syndrome are also associated with increased oral cancer risk. A slight increase in head and neck cancer risk has also been reported in BRCA1/2 mutation carriers.

Pharmacogenomics

In recurrent or metastatic tongue cancer, PD-L1 CPS is used to determine the indication for pembrolizumab monotherapy or combination therapy. A high TMB (tumor mutational burden) may improve the response rate to immunotherapy, and MMR (mismatch repair)-deficient tumors also respond to immunotherapy.


4. General epidemiology

Tongue cancer is the most common subtype of oral cancer worldwide, accounting for about 25–30% of head and neck squamous cell carcinomas. According to GLOBOCAN 2022, about 389,000 new cases of oral cancer (excluding the lip) occur worldwide each year, of which the tongue is a major site.

Epidemiology in Korea

According to data from the Korea Central Cancer Registry of the National Cancer Center, the incidence of tongue cancer in Korea is estimated at about 800–1,100 cases per year. In an analysis of 2001–2021, the incidence of oral tongue cancer increased in both men and women, with a particularly marked increase reported in women aged 45 and under, with an annual percent change (APC) of 6.13%. This may be related to changes in smoking rates among young women, increased HPV exposure, or factors not yet identified. Men have an incidence about 2–3 times higher than women, and the main age of onset is the 50s–70s.

Regional variation

The incidence of tongue cancer is very high in betel nut-chewing cultures such as India, Pakistan and Taiwan. In developed countries, the incidence of oral tongue cancer has somewhat stabilized with declining smoking rates, while in some countries the increase of tongue cancer in young non-smoking, non-drinking women is drawing attention. Incidence is higher and diagnostic delay more frequent in socioeconomically disadvantaged groups.

Site of occurrence

The most common site of oral tongue cancer is the lateral tongue, accounting for about 60–70% of the total. This is followed by the ventral surface (underside), dorsum and tip of the tongue, and tongue cancer of unspecified site (NOS) also makes up a portion.


5. Pathophysiology

The pathogenesis of oral tongue cancer is explained by the multistep carcinogenesis model, progressing from normal mucosa → hyperplastic epithelium → oral epithelial dysplasia (OED) → carcinoma in situ → invasive cancer.

Premalignant lesions and dysplasia

Leukoplakia and erythroplakia are the main premalignant lesions of oral tongue cancer. The malignant transformation rate of mild dysplasia is low, but moderate to severe dysplasia or carcinoma in situ carries a risk of malignant transformation reaching 15–30%. Hyperkeratosis and recurrent ulcers at sites of chronic irritation (lateral tongue) contribute to the precursor lesions.

Major signaling pathways

EGFR/RAS/MAPK pathway: EGFR overexpression → cascade activation of RAS → RAF → MEK → ERK increases cell proliferation, survival and invasion. PI3K/AKT/mTOR pathway: pathway hyperactivation due to PIK3CA mutation or PTEN loss induces protein synthesis, cell growth and inhibition of autophagy. Wnt/β-catenin pathway: nuclear accumulation of β-catenin via APC or CTNNB1 mutation overexpresses genes related to proliferation and differentiation. Notch pathway: NOTCH1 loss-of-function mutations suppress squamous epithelial differentiation, paradoxically promoting carcinogenesis.

Depth of invasion and perineural invasion

Depth of invasion (DOI) is measured at the thickest part of the tumor and affects the T classification according to whether it is under 5 mm, 5–10 mm, or over 10 mm. Increasing DOI is directly linked to increased risk of lymphatic invasion, perineural invasion and cervical lymph node metastasis. Perineural invasion (PNI) is associated with poor prognosis, and extratumoral PNI in particular is an indication for adjuvant radiotherapy.


6. Symptoms

Symptoms of tongue cancer vary by site and stage. The oral tongue (anterior two-thirds) can be directly inspected, making relatively early detection easier, but symptoms may be mild or resemble stomatitis and be mistaken for it.

Early symptoms

The most common initial symptom is a painless ulcer on the lateral or ventral tongue. The ulcer has irregular margins and may bleed, and unlike ordinary stomatitis it characteristically persists for more than 2–3 weeks. Leukoplakia (white patch) or erythroplakia (red patch) may precede it, and at this stage there is almost no pain, so it is often ignored. A sudden hard nodule or a sensation of a mass on the tongue is also an early presentation.

Advanced symptoms

As the tumor grows, glossodynia, pain on chewing and odynophagia appear. As invasion of the tongue muscles worsens, dysarthria and impaired chewing develop. When the tumor invades the nerves of the underside (ventral surface) of the tongue, tongue numbness, pain and paresthesia appear. As invasion toward the base of the tongue progresses, dysphagia becomes prominent. Trismus appears with pterygoid muscle invasion and severely limits oral intake.

Cervical lymph node metastasis and systemic symptoms

A hard, painless palpable mass in the neck suggests cervical lymph node metastasis, and lymph node metastasis is already confirmed in about 30–40% of tongue cancer patients at their first visit. In advanced cancer, systemic symptoms such as weight loss, anorexia and generalized fatigue accompany the disease.


7. Signs

Direct intraoral inspection and bimanual palpation are the core of the physical examination for tongue cancer.

Findings on oral inspection

An ulcerative lesion with irregular margins or an exophytic mass is seen on the lateral tongue (the most common site), ventral surface, dorsum or tip. Leukoplakia or erythroplakia often accompanies the lesion. On bimanual palpation, the tumor is felt as a hard, indurated mass, and the degree of deep invasion can be assessed with the fingers. Restricted tongue movement (unilateral or bilateral fixation) suggests deep muscle invasion.

Neck findings

Palpation of ipsilateral cervical level II, III and IV lymph nodes reveals hard, painless nodules. With extranodal extension (ENE), the lymph nodes adhere to surrounding tissues and are immobile. Tongue cancer can also metastasize to the contralateral neck, so both sides of the neck must be evaluated.

Neurological findings

With hypoglossal nerve (CN XII) invasion, deviation of the tongue toward the paralyzed side is observed. With lingual nerve (CN V3) invasion, reduced sensation of the anterior tongue may appear. There are no specific tumor markers on blood tests, but anemia, hypoalbuminemia and elevated inflammatory markers may accompany the disease.

Imaging findings

On CT it appears as a heterogeneously enhancing mass, and CT is useful for confirming mandibular invasion. MRI is excellent for evaluating the depth of invasion of the tumor, extension into the base of the tongue and perineural invasion. PET-CT is used to search for distant metastasis and synchronous primary tumors.


8. Screening

Because tongue cancer arises at a site that can be directly inspected within the mouth, visual oral examination by appropriately trained health professionals is the most effective screening tool.

National oral cancer screening

Korea's National Cancer Screening Program includes a visual examination for oral cancer, and oral mucosal examination is performed by dentists or otolaryngologists. Ulcers, leukoplakia, erythroplakia or unexplained pain persisting for more than 2 weeks found during screening are indications for immediate referral to a higher-level medical institution.

Surveillance of high-risk groups

For those with a smoking history of 20 or more pack-years or heavy daily drinking, patients with confirmed premalignant lesions, and patients with hereditary risk factors such as Fanconi anemia, oral inspection at 3–6-month intervals and biopsy when necessary are recommended. Immediate correction of chronic tongue irritation due to poor prostheses or sharp teeth is also carried out together with screening.

Oral self-examination

Patients are taught to regularly observe the lateral border, ventral surface and tip of the tongue themselves using a mirror. They are advised to visit a health professional immediately if there are white or red patches, painless ulcers, indurated masses or unexplained pain persisting for more than 3 weeks.

Management of premalignant lesions

Biopsy and classification of oral leukoplakia are essential for assessing the risk of malignant transformation. When dysplasia of moderate grade or higher is confirmed, laser ablation, surgical excision or intensive follow-up is performed. Because erythroplakia has a high rate of malignant transformation, biopsy must be performed.


9. Diagnosis

Imaging

CT (contrast-enhanced, coverage including the jaw): the first-line imaging test, evaluating tumor size and location, mandibular invasion and cervical lymph node metastasis. It is also useful for evaluating extranodal extension of cervical lymph nodes. MRI (T2, contrast-enhanced T1): precisely evaluates the depth of invasion into internal tongue structures, perineural invasion and extension into the base of the tongue. PET-CT: used to rule out distant metastasis and synchronous primary tumors, and is a standard test in clinical stage III-IV.

Tissue biopsy and pathology

Diagnosis must be made by histological confirmation, and incisional biopsy or intraoral punch biopsy is performed. More than about 90% of tongue cancers are squamous cell carcinoma (SCC), and the degree of differentiation (well/moderately/poorly differentiated) affects prognosis. Adenocarcinoma of minor salivary gland origin, lymphoma and melanoma also occur rarely. The pathology report must include depth of invasion (DOI), perineural invasion (PNI), lymphovascular invasion (LVI) and margin status.

Measurement of depth of invasion (DOI) and staging (AJCC 8th edition)

In the AJCC 8th edition, DOI was incorporated into the T classification. T1: size ≤2 cm and DOI ≤5 mm; T2: size >2–4 cm or DOI >5–10 mm; T3: size >4 cm or DOI >10 mm; T4a: invasion of adjacent structures (cortical bone, extrinsic tongue muscles, mandible, etc.); T4b: extensive invasion. Cervical lymph node (N) classification is determined by size, number, laterality and the presence of extranodal extension.

Sentinel lymph node biopsy

In early (T1-T2) tongue cancer with a clinically negative neck (cN0), sentinel lymph node biopsy (SLNB) is being studied as an alternative to elective neck dissection. When SLNB is negative, neck dissection can be omitted, contributing to reduced morbidity.


10. Treatment

Treatment of tongue cancer is decided by the MDT, considering stage, depth of invasion, perineural invasion, margin status, the patient's general condition and functional preservation goals.

Surgery

Surgical resection is the principle of first-line treatment for tongue cancer. For early (T1-T2) tongue cancer, partial glossectomy is sufficient, and the goal is to secure surgical margins of 5 mm or more. When DOI is 4 mm or more, elective neck dissection (selective neck dissection, level I-III) is performed simultaneously. In advanced cases (T3-T4), extensive glossectomy or hemiglossectomy with reconstruction using a free flap (radial forearm free flap or ALT flap) is needed. When the mandible is invaded, segmental mandibulectomy is performed concurrently.

Adjuvant radiation and chemoradiotherapy

When high-risk pathological features (positive margins, perineural invasion, lymphovascular invasion, pN2 or higher, extranodal extension) are present after surgery, adjuvant radiotherapy (adjuvant RT) or concurrent chemoradiotherapy (concurrent CRT) is given. With IMRT/VMAT, 60–66 Gy is prescribed to the primary site and neck. For high-risk features (positive margins, ENE), CRT combined with cisplatin is standard.

Recurrent and metastatic tongue cancer

In recurrent or metastatic disease, based on the KEYNOTE-048 trial, pembrolizumab monotherapy (CPS≥1) or pembrolizumab+cisplatin/carboplatin+5-FU combination is used as first-line treatment. Nivolumab, based on the CheckMate 141 trial, is second-line treatment after platinum failure. Cetuximab+EXTREME combination (cetuximab+cisplatin/carboplatin+5-FU) is also still used. The NCCN guidelines (v1.2026) recommend PD-L1 CPS, TMB and MMR testing before treatment.


11. Prognosis

The prognosis of tongue cancer is largely determined by stage, depth of invasion, perineural invasion, cervical lymph node metastasis and margin status.

5-year survival rate by stage

Stage5-year survival (approximate)Key characteristics
I (T1N0M0)75~85%DOI ≤5 mm, early resection possible
II (T2N0M0)60~70%DOI 5–10 mm, elective neck dissection performed
III (T3 or N1)40~55%Lymph node metastasis, adjuvant treatment needed
IV (T4 or N2-3)20~35%Extensive invasion, combined treatment needed

Impact of lymph node metastasis

A Korean study reported that the 5-year survival rate of patients with cervical lymph node metastasis drops sharply to 22.2%, compared with patients without metastasis (about 85.7%). When extranodal extension (ENE) is present, the prognosis is even worse.

Functional prognosis

Depending on the extent of surgery, the reconstruction method and the radiation field, functional impairments such as swallowing function, speech, xerostomia and taste changes affect long-term quality of life. Speech therapy, swallowing rehabilitation and nutritional support should be integrated into the treatment plan.


12. Prevention

Primary prevention

Smoking cessation is the most effective single intervention in preventing tongue cancer. Smoking cessation is encouraged through cessation support (counseling, nicotine replacement therapy, medication), and exposure to secondhand smoke is also minimized. Moderate drinking: aim to keep alcohol intake to 2 units or less per day or to abstain. Stopping both smoking and drinking reduces the risk of tongue cancer several-fold. Oral hygiene: remove chronic irritation through regular dental checkups, correction of poor prostheses and sharp teeth, and keeping the mouth clean. HPV vaccine: the 9-valent HPV vaccine may contribute to preventing HPV-related oral cancer (including the base of the tongue), but its direct preventive effect on oral tongue cancer is still at the stage of being proven.

Secondary prevention

Regular oral inspection (at least once a year) and the habit of oral self-examination are key to early detection. When premalignant lesions (leukoplakia, erythroplakia, oral lichen planus) are found, immediate referral and follow-up are needed. Because the risk persists in former smokers even after quitting, regular checkups should continue.

Chemoprevention

Retinoids (all-trans retinoic acid) have been studied as inducing regression of oral leukoplakia, but their clinical use is limited because of toxicity and recurrence. The chemopreventive effects of celecoxib, green tea extract (EGCG) and others have been explored in small studies but have not been established as clinical standards.


13. References

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. DOI: 10.3322/caac.21834

  2. Kim M, Kim JH, Kim JY, et al. An epidemiological trend analysis of oral cancer in Korea from 2001 to 2021. BMC Oral Health. 2025;25:567. DOI: 10.1186/s12903-025-06351-1

  3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN. 2025. Available at: https://www.nccn.org

  4. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048). The Lancet. 2019;394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7

  5. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (CheckMate 141). New England Journal of Medicine. 2016;375(19):1856-1867. DOI: 10.1056/NEJMoa1602252

  6. Amin MB, Edge S, Greene F, et al. (eds). AJCC Cancer Staging Manual, 8th Edition. Springer. 2017. ISBN: 978-3-319-40617-6.

  7. Zanoni DK, Migliacci JC, Xu B, et al. Depth of Invasion and Perineural Invasion in Oral Tongue Squamous Cell Carcinoma. JAMA Otolaryngology–Head & Neck Surgery. 2019;145(5):459-467. DOI: 10.1001/jamaoto.2018.4249

  8. Integrated analysis of oral tongue squamous cell carcinoma identifies key variants and pathways linked to risk habits, HPV, clinical parameters and tumor recurrence. Oncotarget. 2016;7(5):5771-5784. DOI: 10.18632/oncotarget.6532

  9. D'Cruz AK, Vaish R, Kapre N, et al. Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer (SEND trial). New England Journal of Medicine. 2015;373(6):521-529. DOI: 10.1056/NEJMoa1506007

  10. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48. DOI: 10.3322/caac.21763